The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to new ...

A decision is expected in the fourth quarter of 2025.

The top sustainable finance executive at HSBC's asset management division is leaving the firm, HSBC said on Friday, the ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The company’s health services division Evernorth is doubling down on a reliable growth area: assuaging payer concerns around ...

CVS Caremark has selected Novo Nordisk’s Wegovy as the preferred GLP-1 medication for its largest commercial template formularies, effective July 1. In March, Novo Nordisk launched NovoCare Pharmacy ...

CVS Health Corp. reported a strong start to 2025, with first-quarter revenue climbing 7%, driven by growth across all business segments.